Recombinant human interferon-β (rHuIFN-β) and radiation therapy for inoperable non-small cell lung cancer

Journal of Interferon and Cytokine Research

Volumn 16, Issue 11, 1996, Pages 891-902

  Byhardt, Roger W ^a   Vaickus, Louis ^b   Witt, Patricia L ^a   Chang, Alex Y ^c   McAuliffe, Timothy ^a   Wilson, J Frank ^a   Lawton, Colleen A ^a   Breitmeyer, James ^b   Alger, Mary Ellen ^b   Borden, Ernest C ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b EMD SERONO INC   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BETA1 INTERFERON; NEOPTERIN; RECOMBINANT BETA INTERFERON; SYNTHETASE;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHO CELL; CLINICAL ARTICLE; DNA SEQUENCE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; PRIORITY JOURNAL;

EID: 0029827192     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.891     Document Type: Article

References (36)

1. BORING, C.C., SQUIRES, T.S., TONG, T., and MONTGOMERY, S. (1994). Cancer statistics. CA-A 44, 7-26.
2. PEREZ, C.A., BAUER, M., EDELSTEIN, S., GILLESPIE, B.W., and BIRCH, R. (1986). Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int. J. Radiat. Oncol. Biol. Phys. 12, 539-547.
3. PEREZ, C.A., STANLEY, K., RUBIN, P., KRAMER, S., BRADY, L.W., MARKS, J.E., et al. (1980). A prospective randomized study of various irradiation dose fractionation schedules in the treatment of inoperative non-small cell lung cancer. Cancer 24, 2744-2753.
4. THAMES, H.D., WITHERS, H.R., PETERS, L.J., and FLETCHER, G.H. (1982). Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationship. Int. J. Radiat. Oncol. Biol. Phys. 8, 219-226.
5. COX, J.D., AZARNIA, N., BYHARDT, R.W., SHIN, K.H., EMAMI, B., and PAJAK, T. (1990). A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 to 79.2 Gy - possible survival benefit with 69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small cell lung carcinoma. Report of Radiation Therapy Oncology Group 83-11. J. Clin. Oncol. 8, 1543-1555.
6. SAUSE, W.T., SCOTT, C., TAYLOR, S., BYHARDT, R.W., BANKER, F.L., THOMSON, H.W., et al. (1992). Phase II trial of combination chemotherapy and irradiation in non-small cell lung cancer, Radiation Therapy Oncology Group 88-04. Am. J. Clin. Oncol. 15, 163-167.
7. DILLMAN, R.O., SEAGREN, S.L., PROPERT, K.J., GUERRA, J., EATON, W.L., PERRY, M.C., et al. (1990). A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. New Eng. J. Med. 323, 940-945.
8. SAUSE, W., SCOTT, C., TAYLOR, S., JOHNSON, D., LIVINGSTON, R., KOMAKI, R., et al. (1994). RTOG 88-08 ECOG 4588, Preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer [abstract]. Proc. Am. Soc. Clin. Oncol. 13, 325 (A1072).
9. BYHARDT, R.W., SCOTT, C.B., ETTINGER, D.S., CURRAN, W.J., DOGGETT, R.L.S., COUGHLIN, C., SCARANTINO, C., ROTMAN, M., and EMAMI, B. (1994). Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small cell lung cancer. Results of Radiation Therapy Oncology Group (RTOG) 90-15. Proc. Am. Soc. Clin. Oncol. 13, 363 (A1222).
10. LEE, J.S., SCOTT, C., KOMAKI, R., FOSSELLA, F., DUNDAS, G.S., McDONALD, S., et al. (1994). Concurrent chemoradiation therapy with oral VP-16 and cisplatin for locally advanced inoperable non-small cell lung cancer (NSCLC): RTOG protocol 91-06 [abstract]. Proc. Am. Soc. Clin. Oncol. 13, 363 (A1222).
11. ASBELL, S., PAJAK, T.F., SEYDEL, H.G., et al. (1990). A phase III RTOG double blind lung cancer trial of XRT and subsequent thymosin or placebo. Proc. Am. Soc. Clin. Oncol. 9, 243.
12. JOHNSON, D.H., EINHORN, L.H., BARTOLUCCI, A., BIRCH, R., OMURA, G., PEREZ, C.A., and GRECO, F.A. (1990). Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann. Intern. Med. 113, 33-38.
13. GOULD, M.N., KAKRIN, R.C., OLSON, S., and BORDEN, E.C. (1984). Radiosensitization of human bronchogenic carcinoma cells by interferon beta. J. Interferon Res. 4, 123-128.
14. CHANG, A.Y.C., and KENG, P.C. (1987). Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle. Cancer Res. 47, 4338-4341.
15. Rebif, Recombinant Human Interferon-beta (rHuIFN-beta) Investigator's Brochure. (1994). Ares Serono And Serono Laboratories, Inc.
16. RINEHART, J., MALSPEIS, L., YHOUNG, D., and NEIDHART, J. (1986). Phase I/II trial of human recombinant beta interferon serine in patients with renal cell carcinoma. Cancer Res. 46, 5364-5367.
17. BORDEN, E.C., HAWKINS, M.J., SIELAFF, K.M., et al. (1988). Clinical and biological effects of recombinant interferon-β administered intravenously daily in a phase I trial. J. Interferon Res. 8, 357-366.
18. WITT, P.L., McAULIFFE, T.L., and SHADLEY, J.D. (1993). Increased cytotoxicity in human lung but not glioma tumor lines by the combination of radiation and interferon-β. Proc. Am. Assoc. Cancer Res. 34, 84.
19. WOLOSHAK, G.E., and CHANG-LIU, C.M. (1990). Differential modulation of specific gene expression following high- and low-LET radiations. Radiat. Res. 124, 183-187.
20. WOLOSHAK, G.E., CHANG-LIU, C.M., JONES, P.S., and JONES, C.A. (1990). Modulation of gene expression in Syrian hamster embryo cells following ionizing radiation. Cancer Res. 50, 339-344.
21. HALLAHAN, D.E., SPRIGGS, D.R., BECKETT, M.A., KUFE, D.W., and WEICHSELBAUM, R.R. (1989). Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing irradiation. Proc. Natl. Acad. Sci. USA 86, 10104-10107.
22. McDONALD, S., CHANG, A.Y., RUBIN, P., WALLENBERG, J., KIM, I.S., SOBEL, S., SMITH, J., KENG, P., and MUHS, A. (1993). Combined Betaseron R (recombinant human interferon Beta) and radiation for inoperable non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 27, 613-620.
23. GOLDSTEIN, D., SIELAFF, K.M., STORER, B.E., BROWN, R.R., DATTA, S.P., WITT, P.A., TEITELBAUM, A.P., SMALLEY, R.V., and BORDEN, E.C. (1989). Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. J. Natl. Cancer Inst. 81, 1061-1068.
24. WITT, P.L., SPEAR, G.T., HELGESON, D.O., LINDSTROM, M.J., SMALLEY, R.V., and BORDEN, E.C. (1990). Basal and interferon-induced 2′5′-oligoadenylate synthetase in human monocytes, lymphocytes and peritoneal macrophages. J. Interferon Res. 10, 393-402.
25. VUNAKIS, H.V., and LANGONE, J.J. (eds.) Methods in Enzymology: Immunological Techniques. Part A, Vol 70, 1980; Part B, Vol 73, 1981. New York: Academic Press.
26. DVORAK, E. (1982). Peracute radiation pneumonitis. Strahlentherapie 158, 23-29.
27. GOLDMAN, A., and ENQUIST, R. (1975). Hyperacute radiation pneumonitis. Chest 67, 613-615.
28. BYHARDT, R., ABRAMS, R., and ALMAGRO, U. (1988). The association of adult respiratory distress syndrome (ARDS) with thoracic irradiation (RT). Int. J. Radiat. Oncol. Biol. 15, 1441-1446.
29. McDONALD, S., RUBIN, P., CHANG, A.Y.C., PENNEY, D.P., FINKELSTEIN, J.N., GROSSBERG, S., FEINS, R., and GREGORY, P.K. (1993). Pulmonary changes induced by combined mouse β-interferon (rMuIFN-β) and irradiation in normal mice - toxic versus protective effects. Radiother. Oncol. 26, 221-218.
30. MAASILTA, P., HOLSTI, L.R., HALME, M., KIVISAARI, L., CANTELL, K., and MATTSON, K. (1992). Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 23, 863-868.
31. HOLSTI, L.R., MATTSON, K., NIIRANEN, A., STANDERTSKIOLD-NORDENSTAM, C.-G., STENMAN, S., SOVIJARVI, A., and CANTELL, K. (1987). Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int. J. Radiat. Biol. Phys. 13, 1161-1166.
32. SHAW, E.G., DEMING, R.L., CREAGAN, E.T., NAIR, S., SU, J.Q., LEVITT, R., STEEN, P.D., WIESENFELD, M., and MAILLIARD, J.A. (1995). Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage IIIA/B non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 31, 827-831.
33. MERRITT, J.A., BORDEN, E.C., and BALL, L.A. (1985). Measurement of 2′,5′ oligo-adenylate synthetase in patients receiving interferon-alpha. J. Interferon Res. 5, 191-98.
34. LIBERATI, A.M., FIZZOTTI, M., PROIETTI, M.G., et al. (1988). Biochemical host response to interferon-beta. J. Interferon Res. 8, 765-777.
35. BORDEN, E.C., HAWKINS, M.J., SIELAFF, K.M., et al. (1988). Clinical and biological effects of recombinant interferon-beta administered intravenously daily in a phase I trial. J. Interferon Res. 8, 357-366.
36. HAWKINS, J., HORNING, S., KONRAD, M., et al. (1985). Phase I evaluation of a synthetic mutant of interferon-β. Cancer Res. 45, 5914-5920.